Centene Still Navigating ACA Adverse Selection Headwinds; DeepValue Report Maintains WAIT

What happened

A Seeking Alpha article characterizes Centene as a defensive shelter amid AI market volatility, but its core thesis revolves around ongoing ACA adverse selection as healthy members depart, leaving a sicker pool. The DeepValue report's WAIT rating, conviction 3.5, and $38 attractive entry reflect this unresolved morbidity risk and the $6.7B goodwill impairment. Centene's aggressive 2026 ACA repricing (mid-30% hikes) aims to restore margins, but membership elasticity and BBBA Medicaid cuts pose substantial headwinds. Operating cash flow of $4.7B in 9M 2025 and RBC >350% provide near-term liquidity, but the stock's 23% decline to ~$47 still discounts a fragile recovery. Until Q4 2025 results and 2026 ACA enrollment data validate margin repair, the risk-reward remains asymmetric, favoring patience.

Implication

Investors should maintain a wait-and-see approach as Centene's ACA adverse selection and Medicaid funding pressures persist. The stock's cheap valuation (~3.8x EV/EBITDA) reflects these risks, but near-term catalysts—Q4 2025 results, 2026 ACA enrollment, and S&P CreditWatch resolution—could either confirm stabilization or trigger further downside. Prudent entry near $38 or after two consecutive quarters of HBR ≤90% offers a better risk-reward than current levels. The article's defensive characterization may be premature; structural margin improvement is not yet proven.

Thesis delta

The Seeking Alpha article's focus on ACA adverse selection and industry algorithm flaws aligns with the DeepValue report's core thesis, reinforcing the structural headwinds. No material shift in the investment case: the WAIT stance remains appropriate, as the article does not provide new evidence of margin recovery. The bull case for Centene as a 'defensive shelter' is premature absent concrete HBR improvement.